Autologous Bone Marrow Transplantation - Blog Science Connections

270 BMT in Relapsed Diffuse Large Cell Lymphoma
Table 1. Frequency of Diffuse Large Cell Lymphoma in Patients With
Non-Hodgkin's Lymphoma Undergoing Autologous Bone Marrow
Transplantation
Group
St. Louis, Vancouver,
Cleveland, Nashville,
Dallas
No. of
Patients with
ABMT for
NHL
No. with
de novo DLCL
70 40 (57%)
University of Nebraska 53 39 (74%)
EBMTG 50 10 (20%)
Minnesota 23 6 (26%)
Abbreviations: ABMT, autologous bone marrow transplantation; NHL, non-
Hodgkin's lymphoma; DLCL, diffuse large cell lymphoma; EBMTG, European Bone
Marrow Transplantation Group.
Table 2. Bone Marrow Transplantation in Patients With
Non-Hodgkin's Lymphoma
No. of Patients in
No. of
Relapse or with
Group Histological Findings Patients Refractory Disease
Seattle Intermediate 82 80 (98%)
and high grade
EBMTG Intermediate 50 34 (68%)
and high grade
University of Diffuse large cell 41 40 (98%)
Nebraska
Dana-Farber Low, intermediate, 39 35 (90%)
and high grade
MSKCC Diffuse large cell 24 11 (46%)
Abbreviations: EBMTG, European Bone Marrow Transplantation Group; MSKCC,
Memorial Sloan-Kettering Cancer Center.
early death rate of 26%. Twenty-five of the 90 patients (27%) continue in
remission for 3+-45+ months with the median remission duration in excess
of 1 year. These results do not vary significantly from those from studies of
relapsed, aggressive non-Hodgkin's lymphomas of mixed histological types.
Approximately 20% of patients with relapsed diffuse large cell lymphoma will
be long-term survivors when treated with high-dose therapy and ABMT.
These results are not greatly different from those seen with allogeneic
transplantation in patients with relapsed acute leukemia (2).